Eloctate 1500 Unit (Antihemophilic Factor (Recombinant Bdd), Fc Fusion Protein KIT) 1500 UNIT

ELOCTATE 1500 Unit is a recombinant antihemophilic factor used for hemophilia B treatment. This intravenous kit helps manage bleeding episodes and prevent complications.

Strength

1500 UNIT

Pack Size

3ML

Manufacturer / TM Owner

SANOFI-AVENTIS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ELOCTATE 1500 Unit is primarily used to control and prevent bleeding in individuals with hemophilia B, a condition characterized by a deficiency in clotting factor IX. This recombinant antihemophilic factor is designed to replace the missing clotting factor, aiding in blood coagulation. It is often administered intravenously to manage bleeding episodes or as a preventive measure before surgeries or dental procedures.

Side Effects

Common effects of ELOCTATE 1500 Unit may include mild reactions at the injection site, such as redness or swelling. Some users might experience headache, nausea, or dizziness. These effects are generally mild and transient, but any persistent or severe reactions should be reported to a healthcare provider.

Precautions & Warnings

ELOCTATE 1500 Unit should be handled with care, ensuring proper storage and administration techniques. It is crucial to follow the instructions provided by a healthcare professional to minimize the risk of adverse reactions. Individuals with known allergies to any components of the kit should avoid its use.

Avoid Interactions

ELOCTATE 1500 Unit may interact with other medications, particularly those that affect blood clotting. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of this treatment.

Frequently Asked Questions

ELOCTATE 1500 Unit is used to manage and prevent bleeding episodes in individuals with hemophilia B.

ELOCTATE 1500 Unit is administered intravenously, typically by a healthcare professional.

Common side effects may include mild reactions at the injection site, headache, nausea, or dizziness.

ELOCTATE 1500 Unit is specifically designed for hemophilia B and should not be used for other types of hemophilia.

Long-term safety should be discussed with a healthcare provider, who can assess individual needs and risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.